488,932 LeMaitre Vascular, Inc. $LMAT Shares Sold by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC reduced its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 35.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 878,581 shares of the medical instruments supplier’s stock after selling 488,932 shares during the period. LeMaitre Vascular makes up about 2.2% of Conestoga Capital Advisors LLC’s holdings, making the stock its 16th biggest holding. Conestoga Capital Advisors LLC owned approximately 3.84% of LeMaitre Vascular worth $72,562,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in LMAT. Boston Trust Walden Corp purchased a new position in LeMaitre Vascular in the third quarter valued at about $28,546,000. Bridge City Capital LLC raised its position in shares of LeMaitre Vascular by 35.5% in the 3rd quarter. Bridge City Capital LLC now owns 116,980 shares of the medical instruments supplier’s stock valued at $9,661,000 after purchasing an additional 30,639 shares in the last quarter. ProShare Advisors LLC raised its position in shares of LeMaitre Vascular by 36.2% in the 3rd quarter. ProShare Advisors LLC now owns 102,571 shares of the medical instruments supplier’s stock valued at $8,471,000 after purchasing an additional 27,270 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $352,000. Finally, Gibbs Wealth Management boosted its stake in shares of LeMaitre Vascular by 6.4% during the 3rd quarter. Gibbs Wealth Management now owns 10,116 shares of the medical instruments supplier’s stock valued at $835,000 after buying an additional 607 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Stock Up 9.1%

Shares of NASDAQ:LMAT opened at $87.92 on Thursday. The company’s fifty day moving average is $81.38 and its two-hundred day moving average is $94.16. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. LeMaitre Vascular, Inc. has a 1-year low of $78.22 and a 1-year high of $118.01. The stock has a market capitalization of $2.01 billion, a price-to-earnings ratio of 30.85, a price-to-earnings-growth ratio of 2.32 and a beta of 0.51.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 EPS for the quarter, missing the consensus estimate of $0.69 by ($0.04). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $67.97 million during the quarter, compared to analyst estimates of $67.39 million. During the same period last year, the firm posted $0.75 earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. Equities analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Thursday, November 19th will be paid a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Thursday, November 19th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 35.09%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on LMAT. Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 23rd. Finally, Wells Fargo & Company reduced their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.